

## Original Research Article

# Isolation and Molecular Detection of Mec-A Gene in Methicillin Resistant *Staphylococcus aureus* Colonizing Anterior Nares of School Children in Jos South, Nigeria

---

### ABSTRACT

**Aims:** This study investigates and reports the carriage of MRSA in students of some Secondary Schools in Jos South Local Government

**Study design:** Cross-sectional study

**Place and Duration of Study:** Molecular biology laboratory, Department of Microbiology, National Veterinary Research Institute, Vom, between February 2016 and March 2017.

**Methodology:** *Staphylococcus aureus* was isolated from the samples using standard cultural and microbiological methods. Antibiotic susceptibility testing was determined as described by the Clinical and Laboratory Standards Institute (CLSI). The detection of MRSA isolates was observed phenotypically using oxacillin and cefoxitin disc diffusion tests. In addition, molecular detection of MRSA *mecA* gene production was carried out using Polymerase Chain Reaction (PCR) method.

**Results:** All samples isolated (100%) had *Staphylococcus sp.* with 114 (29.6%) isolates being *S. aureus*. Antibiotic resistance in the isolates in decreasing order was as follows: ceftazidime (48.2%), augmentin (37.8%), cefuroxime (35.0%), ceftriaxone (23.7%), ampicillin-sulbactam (21.9%), penicillin G (14.9%), ofloxacin (12.2%), gentamycin (11.4%), erythromycin (8.8%), vancomycin (0.0%). Eighteen of the 114 coagulase-positive *S. aureus* isolated (15.8%) were found to be MRSA using the oxacillin disc diffusion test, and thirteen of the MRSA detected (11.4%) identified using cefoxitin disc diffusion test to be also MRSA. The presence of methicillin-resistant gene (*mec A*) was confirmed in four (4) of the 18 MRSA isolates using the PCR technique.

**Conclusion:** The *S. aureus* isolates were less resistant to ampicillin-sulbactam, erythromycin, gentamycin, ofloxacin, and ceftriaxone, with vancomycin showing no resistance. In addition, *mec A* gene was detected in confirmed MRSA isolates.

*Keywords:* *Staphylococcus aureus*; MRSA; antibiotics resistance; susceptibility; gene.

## 1. INTRODUCTION

"*Staphylococcus aureus* is known to be a major pathogen that causes a wide spectrum of clinical manifestations, including skin and soft tissue infections, pneumonia, septicemia, endocarditis, Arthritis, gastroenteritis, meningitis, urinary tract infections, and Toxinoses (such as food poisoning, scalded skin syndrome, and toxic shock Syndrome)" [1-4]. The drugs of choice for therapy are usually beta-lactam antibiotics.

"*Staphylococcus* was first identified in 1880 in Aberdeen Scotland by a Surgeon, Sir Alexander Ogston in pus from a surgical Abscess in a knee joint" [5]. "It is estimated that 20% of the human population are long-term carriers of *Staphylococcus aureus* which can be found as part of the normal skin flora" [6] and in the anterior nares of humans and different animals [7,8]. "Methicillin-Resistant *Staphylococcus aureus* (MRSA) is a strain of the bacterium *Staphylococcus aureus*. It is characterized by antibiotic resistance to methicillin and many other chemotherapeutic agents" [9]. MRSA isolates are resistant to the  $\beta$ -lactam antibiotics. Vancomycin is used to treat MRSA infections. Despite the efforts of researchers to help improve the understanding of the pathogenesis of *S. aureus*, there seems to be an increase in staphylococcal infections.

"*Staphylococcus aureus* has a wide host range and diverse cellular as well as environmental lifestyles. It has the ability to evolve to highly drug-resistant forms that can cause diseases with epidemic potential" [10]. "*S. aureus* exhibits its lifestyle in two ways: a commensal asymptomatic state where it is harbored by 20% or more of the general populations at the anterior nares; and the acute state at which it attacks specific tissues and pathogenicity follows consequently. Generally, *S. aureus* causes infections by self-inoculation (a process whereby the organism breaches the natural barrier) or by direct or indirect contact" [10].

"Antibiotic resistance is a serious public health issue. Some of the factors facilitating antimicrobial resistance are the irrational use of antibiotics by health professionals, unskilled practitioners, and the public; the ready availability of antibiotics as over-the-counter drugs, poor quality of antibiotics unhygienic conditions and inadequate surveillance" [11, 12].

"There is a rise in the prevalence of MRSA globally. It is estimated that MRSA kills more than 40,000 patients every year in the United States alone" [13]. "Data is unavailable to determine the number of patients that are casualties of MRSA in Nigeria. However, from the studies undertaken in Nigeria and the data from a few locations" [14-20], "it is necessary to contain antimicrobial resistance. Based on the WHO antimicrobial resistance global report on surveillance, *S. aureus* is a major bacteria of international concern" [21]. "Some countries have formulated policies and invested in surveillance methods to check this public health issue, however, developing countries need to do more work to address antimicrobial resistance" [22]. Nigeria has developed a national action plan for antimicrobial resistance, 2017-2022, but its implementation years later is still in the early stages with progress difficult to track. In Nigeria, antibiotics are still bought over the counter, thereby increasing the selective pressure of antibiotics when their reduction is a strategy for containing antimicrobial resistance.

There is a need for urgent coordination and collaboration to contain antimicrobial resistance in order to avert a major public health disaster.

This study focuses on the detection of *mec A* genes in MRSA isolates from nares of school children in Jos South, Plateau state, Nigeria.

## 2. MATERIALS AND METHODS

### 2.1 Materials

#### 2.1.1 Media

Bacteriological media that were used in this study included: MacConkey Agar (MCA), Mueller-Hinton Agar (MHA), Nutrient agar (NA), Luria-Bertani (LB) broth, Mannitol Salt Agar (MSA), Nutrient Broth (NB), Blood Agar medium and Peptone water (PW). All the media were sourced from Oxoid Ltd. (U.K.).

### **2.1.2 Equipment**

"The equipment used in this study includes: Autoclave (Certoclav, Model SM280E, Surgifriend Medicals, England), Oven (HotboxSize One, Galenkamp, U.K.), Incubator (Model12-140E, Quincy Lab Inc), Refrigerator/Freezer (Model PRN 1313 HCA, BEKO, Germany), Thermocycler (Model TC-312, Techne, England), Gel electrophoresis machine (Max Fill Scie-plas Model HU10 serial no5237), Laminar air flow cabinet (PCR-8 re-circulating laminar flow pre station, Labcaire product 220/240v), Microscope (Model CME 1349522X, Leica, USA), Spectrophotometer (Eppendorf Biophotometer 8.5 mm, Lichtstrahihöhe), UV illuminator (VilberLourmat TFX-35-M serial no NoV02 8104), Centrifuge (Model 5417R: Touch plate Super Mixer, CAT No 1291, Lab-line Instrument Inc USA), Microwave oven (HINARI Life Style 800watts model MX310TCSL), Electronic weighing balance (Model QT 600: Touch plate Super Mixer, CAT No 1291, Lab-line Instrument Inc USA), Vortex machine (Touch plate Super Mixer, CAT No 1291, Lab-line Instrument Inc USA), and Gel Doc system (Biorad, U.K.)" [32]

### **2.1.3 Chemicals and Reagents**

The chemicals and reagents used in this study included: Carbofuschin, Crystal violet, Ethanol, Creatinine, Potassium hydroxide, and Kovac's reagents, obtained from BDH chemical Ltd, England; Ethidium bromide, Iodine solution, EDTA, and Glycerol obtained from Sigma Chemical Ltd, England; and Agarose gel from Schwarz/ Mann Biotech.

### **2.1.4 Bacteria Isolates**

Confirmed *S. aureus* isolates from the anterior nares were obtained and used for this study. The antibiotic resistance profiles of the isolates are shown in Table 2.

## **2.2 Methods**

### **2.2.1 Antibiotic Susceptibility Testing**

"The antibiotic susceptibility test for *S. aureus* isolates from anterior nares was carried out using the Kirby-Bauer Disc Diffusion method as modified by the Clinical and Laboratory Standards Institute - CLSI [22]. Briefly, 5 colonies of *S. aureus* isolates were inoculated into 5 ml of Mueller-Hinton broth (MHB) and incubated at 37°C for 24 hours after which the 24-hour

MHB was standardized to the turbidity equivalent to 0.5 McFarland standards. The 0.5 McFarland standard was prepared as follows: 99.5 ml of 1% ( $\frac{v}{v}$ )  $H_2SO_4$  + 0.5ml of 1.172% ( $\frac{w}{v}$ )  $BaCl_2 \cdot 2H_2O$ . A sterile cotton swab stick was dipped into the standardized *S. aureus* suspension and streaked on MHA plates. Antibiotic discs were gently placed on the MHA plates using a pair of sterile forceps and the plates were allowed to incubate at room temperature for 1 hour before re-incubating at 37°C for 17 hours. After incubation, the diameters of the zones of inhibition were measured to the nearest millimetre (mm) using a ruler, and the result of the susceptibility test was interpreted using the susceptibility breakpoint earlier described by CLSI" [22].

### **2.2.2 Phenotypic test for MRSA**

All *Staphylococcus aureus* confirmed strains were screened for methicillin resistance using cefoxitin and oxacillin (oxoid) 30ug and 1ug respectively. The discs were placed at a distance of at least 25mm away from each other.

The isolates with inhibition zone diameter of <10mm for oxacillin and <21 mm for cefoxitin were termed **methicillin**-resistant where as those showing a zone diameter of  $\geq 13$ mm for oxacillin and  $\geq 22$ mm for cefoxitin were termed **methicillin**-sensitive Clinical and laboratory standard institute[22].

### **2.2.3 Molecular detection of MRSA *mec A* genes**

Isolates that were MRSA positive were screened to detect the presence of *mec A* gene.

### **2.2.4 DNA Extraction**

The DNA extraction was performed by the boiling method as described previously [23]. Following purification on MacConkey agar, bacterial DNA was isolated from a 24-h culture in Luria-Bertani broth prepared according to the manufacturers' protocol. The bacterial cells were harvested by centrifugation at 3200 rpm in a microcentrifuge for 2 min at room temperature and the supernatant was discarded. The harvested cells were re-suspended in 1 ml of sterile normal saline and the micro-centrifuge tubes were placed in the vortex for 5 sec. Centrifugation was carried out at 3200 rpm for 1 min and the supernatant was discarded. 0.5 ml of sterile normal saline was added to the pellets and the tubes were vortexed for 5 sec after which they were heated in the block heater at 90°C for 10 min. immediately after heating, rapid cooling was done by transferring the tubes into the freezer for 10 min. Cell debris was removed after centrifugation was done at 3200 rpm for 1 min and 300  $\mu$ l of the supernatant was transferred into a sterile 2 ml Eppendorf tube as DNA and stored at -10°C until use.

Estimation of the concentration, purity, and yield of the DNA sample was accessed using the absorbance method (the measurement of absorbance) with the spectrophotometer (Nanodrop 1000, InqabaBiotectm, South Africa). For DNA concentration, absorbance readings were performed at 260 nm (A260) and the readings were observed to be within the instrument's linear range (0.1 – 1.0). DNA purity was estimated by calculating the A260/A280 ratio and this was done by the spectrophotometer's computer software (where A260/A280 ratio ranges from 1.7 – 1.9).

### **2.2.5 DNA amplification of *mec A* genes**

The technique of [23] was used for the polymerase chain reaction (PCR) procedure in this study. The primers (sense) *mecA1* 5'-AAAATCGATGGTAAAGGTTGGC-3' and (antisense) *mecA2* 5' AGTTCTGCAGTACCGGATTTGC-3' (Inqaba, South Africa) were used to detect the presence of *mec A* gene in the methicillin–resistant isolates by yielding a PCR product of 533 bp [23]. The master mix for PCR was performed in a 50  $\mu$ l reaction mixture containing 5  $\mu$ l of a 10X PCR buffer, 1.5 $\mu$ l of a 200  $\mu$ M concentration of each deoxynucleoside triphosphate (dNTP), 2.5  $\mu$ l of a 25 mM MgCl<sub>2</sub>, 0.25  $\mu$ l of a 1.25 unit Taq polymerase (Biolab, South Africa), 1  $\mu$ l of a 10pM of each primer and 0.25  $\mu$ l of a 2.5  $\mu$ l of DNA template. DNA amplification was carried out using GeneAmp<sup>R</sup> PCR System9700 (Applied Biosystems, U.S.A) for 50 cycles in 50  $\mu$ l of reaction mixture as follows: initial denaturation at 95°C for 2 minutes, denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds and extension at 72°C for 1 minute with a final extension at 72°C for 5 minutes, then kept at 4°C.

### **2.2.6 Agarose Gel electrophoresis**

PCR products (10  $\mu$ l) **were** electrophorised in 1.5% agarose gel. (The gel containing 5  $\mu$ l of 10mg/ml ethidium bromide solution) at 100 volts for 60 minutes, as per the protocol by Rajamani [24]. 50 bp DNA marker (Fermenter<sup>R</sup>) was used as the molecular size marker. The Amplicons were visualized under **an** automatic molecular imaging transilluminator (Gel DOC<sup>TM</sup> XR+ BIORAD, U.S.A) to check for the presence of the DNA PCR products at 533bp and the image was stored in the computer.

## **3. RESULTS AND DISCUSSION**

### 3.1 Age and Sex Distribution of the Study Population

A total of 385 students were enrolled in this study, out of which 173 were male and 212 were female, with male to female ratio of 1.6:2. as shown in table 1.

**Table 1. Age and Sex Distribution of the Study Population**

Schools	Age (10-15yrs)	Age (16-21yrs)	Female (%)	Male (%)
GSS Rantya	46 (11.9)	33 (8.6)	31 (8.1)	48 (12.5)
GSS Kufang	99 (25.7)	110 (28.5)	126 (32.7)	83 (21.6)
Sacred Heart	74 (19.2)	23 (5.9)	55 (14.2)	42 (10.9)
Total	219 (56.9)	166 (43.1)	212 (55.0)	173 (45.0)

### 3.2 Antimicrobial Resistance Profile


The antimicrobial resistance in the *S. aureus* isolates from the anterior nares of school children are shown in Table 1. The resistance in the isolates was as follows ceftazidime (48.2%), augmentin (37.8%), cefuroxime (35.0%), ceftriaxone (23.7%), ampicillin-sulbactam (21.9%), penicillin G (14.9%), ofloxacin (12.2%), gentamycin (11.4%), erythromycin (8.8%), vancomycin (0.0%).

**Table 2. Antimicrobial Resistance and Sensitivity Pattern of *Staphylococcus aureus* isolates (n=114)**

Antibiotic	Resistance (%)	Sensitivity (%)
Augmentin	43 (37.8)	71 (62.2)
Ceftazidime	55 (48.2)	59 (51.8)
Ceftriaxone	27 (23.7)	87 (76.3)
Cefuroxime	40 (35.0)	74 (65.0)
Penicillin G	17 (14.9)	97 (85.1)
Erythromycin	10 (8.8)	104 (91.2)
Gentamycin	13 (11.4)	101 (88.6)
Ofloxacin	14 (12.2)	100 (87.8)
Ampicilin-Sulbactam	25 (21.9)	89 (78.1)
Vancomycin	0 (0)	114 (100)

### 3.3 Biochemical Test for Isolates

Out of the 385 *Staphylococci species*, 114 were confirmed by biochemical tests to be coagulase positive (*Staphylococcus aureus*) while 271 were coagulase-negative giving 29.6% and 70.4% respectively as represented in the pie chart as shown in Figure 1.



### 3.4 Phenotypic Confirmation of MRSA

Out of the 114 coagulase-positive *Staphylococcus aureus* isolated, eighteen (18) were found to be MRSA using oxacillin disc diffusion test which gave a prevalence of 15.8% among *S. aureus* isolates, and overall prevalence among the study population of 4.7%. Only thirteen (13) of the MRSA detected were identified using cefoxitin disc diffusion test to be also MRSA, thereby giving a prevalence of MRSA among *S. aureus* isolates of 11.4% and overall of 4.7% as shown in Table 3.

**Table 3. Frequency of MRSA among the coagulase-positive staphylococcus aureus isolates (n=114)**

Confirmatory Test	Number	Frequency
	114	29.6
MRSA (oxacillin disc)	R 18	15.8
	S 96	84.2
MRSA (cefoxitin disc)	R 13	11.4
	S 101	88.6
Overall Prevalence (n= 385)	18	4.7


Key: **R**=Resistant **S**=Sensitive

### 3.5 Molecular Detection of *mec A* Genes

The presence of a methicillin-resistant gene was confirmed using PCR technique. Four(4) of the 18 MRSA isolates were confirmed *mec A* positive as evidenced by the amplification of *mec A* gene at the specific amplicon of 533bp fig: 2. Hence, the *mec A* gene isolation rate among *staphylococcus aureus* isolates( n=114) was 3.51% and an overall (n=385) was 1.04% as shown in Table 4.

**Table 4. The isolation rate of *mec A* gene among the *S. aureus*.**

	Number	Frequency (%)
<i>mec A</i> gene prevalence among <i>S. aureus</i> isolates (n=114)	4	3.51
Overall <i>mec A</i> gene prevalence among students (n=385)	4	1.04



**Fig 2:** PCR showing four amplicons produced by four isolates at 533bp with a 100bp molecular marker.

### 3.6 Discussion

“Antibiotic resistance has been described as one of the paramount microbial threats of the 21st century” [25]. “*Staphylococcus aureus* has always been a stumbling block for antimicrobial chemotherapy, and the introduction of new classes of antimicrobial agents is usually followed by the emergence of resistant forms of this pathogen” [26]. “Methicillin-resistant *Staphylococcus aureus* (MRSA) has been proven to be a globally- spread nosocomial pathogen of the 20<sup>th</sup> century” [27]. Therefore, surveillance of the antimicrobial susceptibility patterns of *S. aureus* is of utmost importance in understanding new and

emerging resistance trends, and in the management of both hospital and community-acquired infections. In the antimicrobial-resistant profile, it has been shown that Ceftazidime exhibited the highest resistance pattern, while Vancomycin showed no resistance. Vancomycin can therefore be used for the treatment of *Staphylococcus aureus* as well as other antibiotics such as Ampicillin, Gentamycin, Ofloxacin, and Ceftriaxone which showed low resistance.

In the antibiotic susceptibility testing it was observed that Erythromycin had the highest number of isolates sensitive to it i.e., 104 isolates giving a percentage of 91.2% as opposed to Ceftazidime with the lowest number of isolates 59 (51.8%; n=114). Data on MRSA strains in most sub-Saharan African countries, cast a shadow on the public health implication and awareness of the organism. Information from this study intends to provide the baseline data, for eventual appreciation of the need for cautious approach and intervention measures.

In this study, the MRSA prevalence of 4.7% (phenotypic) and 1.04 % (genotypic) may be considered to be low, especially as there isn't any previous epidemiological data on MRSA in this area among school children. "Although, MRSA prevalence is known to vary with geographical location, type of health institutions, studied population, and method of detection employed. However, our MRSA prevalence may be considered very low, when compared with a similar study in Ibadan, Southwestern Nigeria with a prevalence level of 20.3%" [28], as both phenotypic and molecular methods were employed. Previous studies on "MRSA in southwestern Nigeria with the same detection methods, reported a prevalence of less than 2%" [25, 29]. "Oxacillin disc diffusion method was the earliest method of detection for methicillin resistance expression. Because of low specificity and sensitivity, cefoxitin disc diffusion was introduced by CSLI, which is known as a good surrogate marker of *mec A* gene detection" [30, 31]. Earlier MRSA prevalence reported from Nigeria was based on phenotypic methods using oxacillin.

#### 4. CONCLUSION

A low percentage of secondary school children in Jos are carriers of multi-drug-resistant *Staphylococcus aureus*. The *S. aureus* isolates were more resistant to augmentin (37.8%), cefuroxime (35.0%), ceftriaxone (23.7%), ampicillin-sulbactam (21.9%), penicillin G (14.9%), ofloxacin (12.2%), gentamycin (11.4%), erythromycin (8.8%), vancomycin (0.0%). This implies that antibiotics could be useful in MRSA infections.

#### CONSENT

The informed written consents of the students/ patients were obtained before sample collection.

#### ETHICAL APPROVAL

All authors hereby declare that all experiments have been examined and approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

#### REFERENCES

1. Grisold AJ, Leitner E, Mühlbauer G, Marth E, Kessler HH, Detection of methicillin-resistant *Staphylococcus aureus* and simultaneous confirmation by automated nucleic acid extraction and real-time PCR," *Journal of clinical microbiology*. 2002: 40 (7), 2392-2397.

2. Ibadin EE, Enabulele IO, Muinah F. "Prevalence of *mecA* gene among staphylococci from clinical samples of a tertiary hospital in Benin city, Nigeria," *African health sciences*. 2017: 17(4), 1000-1010.
3. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG. "*Staphylococcus aureus* infections: Epidemiology, pathophysiology, clinical manifestations, and management," *Clinical microbiology reviews*. 2015: 28 (3), 603-661.
4. Taylor TA, Unakal CG. "*Staphylococcus aureus*," In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019.
5. Ogston A. "on Abscess" classic infection Disease" *Rev. Infect. Dis.* 1984: 6 (1) 122 – 128
6. Kluytmans, J., van Belkum, A., & Verbrugh, H. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clinical Microbiology Reviews*. 1997: 10(3), 505-520.
7. Wertheim HFL, Voss MC, Ott A, Van Belkum A, Voss A, Yolken R. H. (ASM Press Washington D.C) 6<sup>th</sup> ed.; 282 – 298.
8. Weese JS, Duizkeren VE. Methicillin Resistant *Staphylococcus aureus* and *Staphylococcus Pseuel Intermechius* in Veterinary Medicine, *Vet. Microbiol.* 2010:140: 418 – 429
9. Maurean UO, Okwu Tonye GO, Olley M, Eguagle OO. *Canadian Epen biological Science Journal*. 2014: 1(1), 1 -12
10. Crossley KB, Jefferson KK, Archer GL, Fowler VG. *Staphylococci in human disease*. : John Wiley & Sons, Singapore; 2009.
11. Okeke IN, Lamikanra A, Edelman R. "Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries," *Emerging infectious diseases*. 1999: 5 (1)18-27.
12. Chokshi A, Sifri Z, Cennimo D, Horng H. "Global contributors to antibiotic resistance," *Journal of global infectious diseases*. 2019: (11)1, 36-42.
13. Adetayo TO, Deji-Agboola AM, Popoola MY, Atoyebi TJ, Egberongbe KJ. "Prevalence of methicillin resistant *Staphylococcus aureus* from clinical specimens in Ibadan, Nigeria," *International Journal of Engineering Science*. 2014: (3), 1-11.
14. Ajoke OI, Okeke IO, Odeyemi OA, Okwori A. "Prevalence of methicillin-resistant staphylococcus aureus from healthy community individuals volunteers in Jos south, Nigeria," *Journal of Microbiology, Biotechnology and Food Sciences*. 2020: 9(5), 1389-1405.
15. Bunza NM, Isah AA, Hafsat MD, Asiya UI. "Antibiotic susceptibility pattern of *Staphylococcus aureus* isolated from clinical samples in specialist hospital, Sokoto," *South Asian Journal of Research in Microbiology*. 2019: 1-6.
16. Ike B, Ugwu MC, Ikegbunam MN, Nwobodo D, Ejikeugwu C, Gugu T, Esimone CO. "Prevalence, antibiogram and molecular characterization of community-acquired methicillin-resistant *Staphylococcus aureus* in Awka, Anambra Nigeria," *The open microbiology journal*. 2016:10, 211-221.
17. Osinupebi OA, Osiyemi JA, Deji-Agboola AM, Akinduti PA, Ejilude O, Makanjuola SO, Sunmola NO, and Osiyemi EO. "Prevalence of methicillin-resistant *Staphylococcus aureus* in Abeokuta, Nigeria," *South Asian Journal of Research in Microbiology*. 2018: 1-8.

18. Ghebremedhin B, Olugbosi MO, Raji AM Layer F, Bakare RA, König B, König W. "Emergence of a community-associated methicillin-resistant *Staphylococcus aureus* strain with a unique resistance profile in southwest Nigeria," *Journal of clinical microbiology*. 2009; 47, 9. 2975-2980.
19. Udeani TK, Onyebuchi CJ, Ikpenwa MC, Ezenwaka UR. "Prevalence and antibiotic susceptibility pattern of methicillin resistant *Staphylococcus aureus* in burns and pressure ulcer patients," *African Journal of Clinical and Experimental Microbiology*. 2016; 17, 2, 130-139.
20. World Health Organization, "Antimicrobial resistance global report on surveillance: 2014 summary," *Antimicrobial resistance global report on surveillance: 2014 summary*, 2014. <https://www.who.int/publications/i/item/WHO-HSE-PED-AIP-2014.2>
21. Chaudhary AS. "A review of global initiatives to fight antibiotic resistance and recent antibiotics' discovery," *Acta Pharmaceutica Sinica B*. 2016; 6 (6), 552-556.
22. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 15<sup>th</sup> informational supplement M100–S15. *Clinical and Laboratory Standards Institute*, 2012.
23. Porteous LA, Armstrong JL, Seidler RJ, Watrud LS. An effective method to extract DNA from environmental samples for polymerase chain reaction amplification and DNA fingerprint analysis. *Current microbiology*. 1994; 29(5): 301-307.
24. Rajamani M, JESTEENA J, and R RAGUNATHAN. "Detection of *mecA* gene associated with methicillin resistant *Staphylococcus aureus* and its alternatives using nanoparticles and chia seeds." *International Journal of Medical Research & Health Sciences*. 2017; 6(11): 67-75.
25. Shittu AO, Lin J, Morrison D, Kolawole DO. The discovery of a multi-resistant *Staphylococcus haemolyticus* clone in the hospital and community environment in south western Nigeria. *Ostomy Wound Manage*. 2005; 51(1):67–70.
26. Kesah C, Ben Redjeb S, Odugbemi TO. Prevalence of methicillin-resistant *Staphylococcus aureus* in eight African hospitals and Malta. *Clin Microbiol Infect*. 2003; 9 (2):153–156.
27. Nimmo,GR, Schooneveldt JO, O’Kane G.,Mcall B and Vickery A. Community acquisition of gentamycin sensitive methicillin resistant *Staphylococcus aureus* in South East Queensland, Australia. *Journal of clinical microbiology*. 2000;38(11):3926-3931.
28. Hageman JC, Morrison M. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network Methicillin-resistant *Staphylococcus aureus* disease in three communities. *N Engl J Med*. 2005; 352(14):1436–1444.
29. Owolabi JB, Olorioke RC, "Prevalence and antimicrobial susceptibility of methicillin resistant *Staphylococcus aureus* and coagulase-negative staphylococci isolated from apparently healthy university students in Ota, Nigeria,". *Journal of Natural Sciences Research*.2015;5(24):40-48.
30. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, Lin F, Lin J, Carleton HA, Mongodin EF, "Complete genome sequence of USA300, an epidemic

clone of community-acquired methicillin-resistant *Staphylococcus aureus*," *The Lancet*. 2006: 367, 731-739.

31. Becker K, Harmsen D, Mellmann A, Meier C, Schumann P, Peters G, & von Eiff C. Development and evaluation of a quality-controlled ribosomal sequence database for 16S ribosomal DNA-based identification of *Staphylococcus* species.

*Journal of Clinical Microbiology*. 2004: 42(11), 4988-4995.

doi:10.1128/JCM.42.11.4988-4995.

32. Tama SC, Ngwai YB, Nkene IH, Abimiku RH. Molecular Detection of Extended Spectrum Beta-lactamase Resistance in *Escherichia coli* from Poultry Droppings in Keffi, Nigeria. *Asian Journal of Medicine and Health*. 2019;15(4):1-9.